Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Long-Term Debt Repayments (2020 - 2023)

Rapid Therapeutic Science Laboratories' Long-Term Debt Repayments history spans 4 years, with the latest figure at $14500.0 for Q2 2023.

  • For Q2 2023, Long-Term Debt Repayments fell 63.2% year-over-year to $14500.0; the TTM value through Jun 2023 reached $287201.0, up 628.94%, while the annual FY2022 figure was $287900.0, 4.03% down from the prior year.
  • Long-Term Debt Repayments for Q2 2023 was $14500.0 at Rapid Therapeutic Science Laboratories, down from $24201.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $300000.0 in Q1 2021 and bottomed at $14500.0 in Q2 2023.
  • The 4-year median for Long-Term Debt Repayments is $59100.0 (2022), against an average of $110943.0.
  • The largest YoY upside for Long-Term Debt Repayments was 63.2% in 2023 against a maximum downside of 63.2% in 2023.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $150000.0 in 2020, then skyrocketed by 100.0% to $300000.0 in 2021, then plummeted by 36.87% to $189400.0 in 2022, then tumbled by 92.34% to $14500.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Long-Term Debt Repayments are $14500.0 (Q2 2023), $24201.0 (Q1 2023), and $189400.0 (Q4 2022).